Tag Archive for: appointments

Resolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer

/in

Highly experienced Chief Financial Officer set to drive corporate and strategic goals of Resolution. Accomplished Chief Business Officer will drive business development and partnering deals. Appointments follow the announcement of the first patient dosed and safety cleared in its Phase I/II EMERALD study. Edinburgh and London, UK 10 September 2025 – Resolution Therapeutics (“Resolution” or “Company”), a clinical-stage biopharmaceutical […]

Read more

Asgard Therapeutics strengthens its Board of Directors and Advisory Board with leading experts in drug development and cancer immunotherapy

/in

Highly experienced biopharma executive Dr Cristina Csimma joins Asgard’s Board of Directors, while esteemed immunologists Prof Ignacio Melero and Prof Brian Brown join Advisory Board Appointments strengthen Asgard’s team as it progresses IND-enabling studies for its lead asset AT-108 – a first-in-class, off-the-shelf cell reprogramming therapy that leads to personalized and potent anti-cancer immune responses […]

Read more

iOnctura bolsters leadership team with new appointments

/in

Steven Sciuto joins as Chief Financial Officer (CFO) bringing a wealth of experience in scaling finance functions as well as in private and public financings Michelle Tsai PharmD, with deep expertise in portfolio strategy and lifecycle planning, joins as Chief Operating Officer (COO) Geneva, Switzerland and Amsterdam, The Netherlands, 2 June 2025 – iOnctura, a […]

Read more

Astraveus Strengthens Leadership Team and Board

/in

Jean-Paul Mangeolle joins as Chairman of the Board of Directors David Newble appointed as an Independent Board Member Laurence Riot Lamotte appointed as Chief Financial Officer New hires reflect continuing progress at Astraveus as Company prepares for launch of the Lakhesys Benchtop Cell FactoryTM Paris, France, 15 April 2025 – Astraveus SAS (“Astraveus” or the […]

Read more

Ottimo Pharma Strengthens Leadership Team with Senior Appointments

/in

Robert Tighe appointed as Senior Vice President of Preclinical and Translational Sciences and Katherine Bell-McGuinn, M.D., Ph.D. appointed as Senior Vice President of Clinical Development  Appointments support Ottimo Pharma as it rapidly advances the clinical development of lead candidate, Jankistomig, its first-in-class dual pathway, biparatopic IgG1 therapy  IND clearance for Jankistomig is on track for […]

Read more
© Optimum Strategic Communications.